US 11,787,861 B2
Anti-CD200R1 antibodies and methods of use thereof
Yu Chen, Foster City, CA (US); Jilean Beth Fenaux, San Mateo, CA (US); Germaine Fuh-Kelly, Pacifica, CA (US); Yao-Ming Huang, San Mateo, CA (US); Wei-Jen Chung, El Granada, CA (US); Erik Edward Karrer, Los Altos, CA (US); Cecilia Lay, Brisbane, CA (US); Steven J. Pitts, San Francisco, CA (US); and Louise Scharf, Redwood City, CA (US)
Assigned to 23andMe, Inc., Sunnyvale, CA (US)
Filed by 23andMe, Inc., Sunnyvale, CA (US)
Filed on May 28, 2021, as Appl. No. 17/333,963.
Claims priority of provisional application 63/032,508, filed on May 29, 2020.
Prior Publication US 2021/0371521 A1, Dec. 2, 2021
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 30 Claims
 
1. An anti-CD200R1 antibody comprising (i) a first light chain hypervariable region (HVR-L1), a second light chain hypervariable region (HVR-L2), and a third light chain hypervariable region (HVR-L3); and (ii) a first heavy chain hypervariable region (HVR-H1), a second heavy chain hypervariable region (HVR-H2), and a third heavy chain hypervariable region (HVR-H3), comprising:
(a) HVR-L1 of SEQ ID NO: 11, HVR-L2 of SEQ ID NO: 12, and HVR-L3 of SEQ ID NO: 13; and HVR-H1 of SEQ ID NO: 15, HVR-H2 of SEQ ID NO: 16, and HVR-H3 of SEQ ID NO: 17;
(b) HVR-L1 of SEQ ID NO: 19, HVR-L2 of SEQ ID NO: 20, and HVR-L3 of SEQ ID NO: 21; and HVR-H1 of SEQ ID NO: 23, HVR-H2 of SEQ ID NO: 24, and HVR-H3 of SEQ ID NO: 25;
(c) HVR-L1 of SEQ ID NO: 27, HVR-L2 of SEQ ID NO: 28, and HVR-L3 of SEQ ID NO: 29; and HVR-H1 of SEQ ID NO: 31, HVR-H2 of SEQ ID NO: 32, and HVR-H3 of SEQ ID NO: 33;
(d) HVR-L1 of SEQ ID NO: 35, HVR-L2 of SEQ ID NO: 36, and HVR-L3 of SEQ ID NO: 37; and HVR-H1 of SEQ ID NO: 39, HVR-H2 of SEQ ID NO: 40, and HVR-H3 of SEQ ID NO: 41;
(e) HVR-L1 of SEQ ID NO: 43, HVR-L2 of SEQ ID NO: 44, and HVR-L3 of SEQ ID NO: 45; and HVR-H1 of SEQ ID NO: 47, HVR-H2 of SEQ ID NO: 48, and HVR-H3 of SEQ ID NO: 49;
(f) HVR-L1 of SEQ ID NO: 51, HVR-L2 of SEQ ID NO: 52, and HVR-L3 of SEQ ID NO: 53; and HVR-H1 of SEQ ID NO: 55, HVR-H2 of SEQ ID NO: 56, and HVR-H3 of SEQ ID NO: 57;
(g) HVR-L1 of SEQ ID NO: 59, HVR-L2 of SEQ ID NO: 60, and HVR-L3 of SEQ ID NO: 61; and HVR-H1 of SEQ ID NO: 63, HVR-H2 of SEQ ID NO: 64, and HVR-H3 of SEQ ID NO: 65;
(h) HVR-L1 of SEQ ID NO: 77, HVR-L2 of SEQ ID NO: 78, and HVR-L3 of SEQ ID NO: 79; and HVR-H1 of SEQ ID NO: 81, HVR-H2 of SEQ ID NO: 82, and HVR-H3 of SEQ ID NO: 83;
(i) HVR-L1 of SEQ ID NO: 11, HVR-L2 of SEQ ID NO: 12, and HVR-L3 of SEQ ID NO: 13; and HVR-H1 of SEQ ID NO: 85, HVR-H2 of SEQ ID NO: 86, and HVR-H3 of SEQ ID NO: 87;
(j) HVR-L1 of SEQ ID NO: 11, HVR-L2 of SEQ ID NO: 12, and HVR-L3 of SEQ ID NO: 13; and HVR-H1 of SEQ ID NO: 81, HVR-H2 of SEQ ID NO: 82, and HVR-H3 of SEQ ID NO: 83; or
(k) HVR-L1 of SEQ ID NO: 77, HVR-L2 of SEQ ID NO: 78, and HVR-L3 of SEQ ID NO: 79; and HVR-H1 of SEQ ID NO: 85, HVR-H2 of SEQ ID NO: 86, and HVR-H3 of SEQ ID NO: 87.